Status: Not yet recruiting
Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients
Preclinical data indicate that rifaximin could be repurposed as a novel strategy for preventing and reducing the severity of gastrointestinal damage, particularly diarrhea, that results from pelvic irradiation. So, The aim of the work is to investigate the impact of Rifaximin on the incidence and severity of radiotherapy-induced diarrhea in cancer patients undergoing pelvic irradiation with or without chemotherapy.
Participants needed: 80
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Mansoura UniversityUpdated: Jan 20, 2025Locations: 1
Eligibility criteria
Individuals who are 18 years of age or older and have been diagnosed with non me... [+1]
Patients who have a record of intestinal resection in their medical history. [+7]